1.Efficacy of gastrodin injection combined with dexamethasone in the treatment of sudden deafness and its effect on hemorheology and hearing
Yan SHI ; Qian XUE ; Meichang LIU
Chinese Journal of Primary Medicine and Pharmacy 2021;28(4):558-562
Objective:To investigate the efficacy of gastrodin injection combined with dexamethasone in the treatment of sudden deafness and its effect on hemorheology and hearing.Methods:Eighty patients with sudden deafness who received treatment in the Department of Otolaryngology, General Hospital of Taiyuan Iron and Steel (Group) Co., Ltd., from August 2018 to March 2020 were included in this study. These patients were randomly assigned to receive either intratympanic injection of dexamethasone (control group, n = 40) or intratympanic injection of dexamethasone combined with gastrodin injection (treatment group, n = 40). Total effective rate was compared between the two groups. The auditory threshold at 0.5, 1.0, 2 and 4 kHz was measured in each group. Before and after treatment, plasma viscosity, low shear whole blood viscosity, fibrinogen and erythrocyte deformability index were compared between the two groups. Drug-related adverse reactions were recorded in each group. Results:Total effective rate in the treatment group was significantly higher than that in the control group [92.50% (37/40) vs. 75.00% (30/40), χ2 = 4.401, P < 0.05]. After treatment, the auditory threshold at 0.5, 1.0, 2 and 4 kHz was significantly decreased compared with before treatment in each group (all P < 0.001). After treatment, the auditory threshold at 0.5, 1.0, 2 and 4 kHz was (42.71 ± 7.06) dB, (44.01 ± 9.35) dB, (48.06 ± 11.37) dB and (52.40 ± 14.26) dB, respectively, in the treatment group and (50.14 ± 8.09) dB, (53.70 ± 10.46) dB, (55.10 ± 13.47) dB and (59.26 ± 15.77) dB respectively in the control group. There were significant differences between the two groups ( t = 4.376, 4.368, 2.526 and 2.267, all P < 0.05). After treatment, plasma viscosity, low shear whole blood viscosity and fibrinogen in each group were significantly decreased (all P < 0.001). After treatment, erythrocyte deformability index in each group was significantly increased ( P < 0.001). After treatment, plasma viscosity, low shear whole blood viscosity and fibrinogen were significantly decreased, and erythrocyte deformability index was significantly increased, compared with before treatment in each group. After treatment, plasma viscosity, low shear whole blood viscosity and fibrinogen, and erythrocyte deformability index were (1.68 ± 0.39) mPa · s, (19.07 ± 3.65) mPa · s, (3.11 ± 0.58) g/L, (0.68 ± 0.08), respectively in the treatment group, and (2.01 ± 0.41) mPa · s, (22.10 ± 4.49) mPa · s, (3.89 ± 0.75) g/L, (0.60 ± 0.07) respectively in the control group. There were significant differences in plasma viscosity, low shear whole blood viscosity and fibrinogen, and erythrocyte deformability index between the two groups ( t = 3.688, 3.312, 5.203, 4.760, all P < 0.05). There was no significant difference in the incidence of adverse reactions between the treatment and control groups (10.00% vs. 15.00%, χ2 = 0.457, P > 0.05). Conclusion:Gastrodin injection combined with dexamethasone can enhance the curative effect on sudden deafness, effectively improve patient's hemorheology and hearing, and is highly safe.
2.Clinical application of cryoprecipitate in the treatment of skull base fracture hemorrhage
Taotao PAN ; Jianping LIU ; Chengnuan LAO ; Wenbiao CHEN ; Meichang JIANG ; Jianming GUAN
Chinese Journal of Primary Medicine and Pharmacy 2016;23(10):1497-1499
Objective To investigate the cryoprecipitate fracture hemorrhage clinical application value in the skull fracture hemorrhage,and provide reference for clinical treatment.Methods 80 patients with standard skull frac-ture hemorrhage were selected as the research subjects.The patients were randomly divided into observation group (40 cases)and the control group (40 cases).The control group was given hemostasis,dehydration,protecting stom-ach,antibacterial,nerve nutrition,reducing intracranial pressure,head up in bed and other symptomatic treatment.The observation group received the treatment besides in the control group and added the cryoprecipitate hemostasis,every time given 10U,every 6 -8h 1 time.According to the condition,they were given the cold sediment of 1 -3 times. Then,the cases that fit to give surgery we must cured them by the operation.After treatment 24h,the coagulation inde-xes were examined [prothrombin time (PT),activated partial thromboplastin time (APTT),thrombin time (TT),two D -dimer],plasma fibrinogen (Fbg),International Glasgow (GOS).Finally,we observed clinical prognosis in two groups.Results PT,APTT,TT were significantly shorter than before treatment in the observation group and the con-trol group(t =6.654,5.746,6.193 and 3.342,3.552,3.646,P <0.01 or P <0.05).The PT,APTT and TT of the observation group were significantly shorter than those in the control group (t =3.322,3.406,3.315,all P <0.05). Plasma Fbg was significantly higher than before treatment in two groups(t =5.762,3.592,P <0.01 or P <0.05). Fbg in the observation group was significantly higher than the control group(t =3.407,P <0.05).The clinical prog-nosis in the observation group was significantly better than the control group(χ2 =8.747,P <0.05).Conclusion Cryoprecipitate is a safe and efficient drug.It can effectively improve the blood coagulation dysfunction of patients with fracture of skull base,active endogenous coagulation system,improve hemostatic effect,and reduce the occurrence of progressive cerebral hemorrhage.Therefore,it can improve the prognosis of patients.